Susquehanna International Securities’s Indivior Pharmaceuticals INDV Stock Holding History

Susquehanna International Securities’s Portfolio INDV Stock Details INDV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-12,257	Closed	-$263K	–	67
2024 Q1	$263K	Sell	12,257 -6,701	-35%	-$126K	0.1%	42
2023 Q4	$290K	Buy	18,958 +9,277	+96%	+$165K	0.21%	42
2023 Q3	$219K	Sell	9,681 -696	-7%	-$15.9K	0.19%	29
2023 Q2	$249K	Buy	+10,377	New	+$238K	0.23%	34

Other funds holding INDV

TSC

Two Seas Capital Rye, New York $7.15B AUM 169.27% 1-Year Est. Return

MGP

M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

SCM

Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return

Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OCM

Oaktree Capital Management Los Angeles, California $6.56B AUM 42.97% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Susquehanna International Securities's INDV Position: Q2 2024 in Review

Susquehanna International Securities sold out of Indivior Pharmaceuticals (INDV) in Q2 2024, closing a stake of 12,257 shares — an estimated $263K sold.

Susquehanna International Securities first reported a position in INDV in Q2 2023 and held it in 4 quarters. The position peaked at $290K in Q4 2023. 99 funds tracked by Wall St. Rank hold INDV as of Q2 2024.

Susquehanna International Securities reported no remaining Indivior Pharmaceuticals position as of Q2 2024 after selling out during the quarter.
Susquehanna International Securities sold 12,257 Indivior Pharmaceuticals shares in Q2 2024, an estimated $263K.
Susquehanna International Securities first reported a position in Indivior Pharmaceuticals in Q2 2023 and held it in 4 quarters.
Susquehanna International Securities's Indivior Pharmaceuticals position peaked at $290K in Q4 2023.
99 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2024.

Based on Susquehanna International Securities's 13F filing for Q2 2024, filed 15 Aug 2024.